In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Section D, participants will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment till disorder progression or the participants are not able to tolerate the study drugs. There might be higher treatment load for members in this trial when compared https://franciscordnyi.liberty-blog.com/32053027/abbv-744-in-combination-with-immunotherapy-an-overview